Drugs / Lacticaseibacillus rhamnosus HA-114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02962583 | Jan 2017 → Jun 2019 | obesity disorder | Laval University | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacticaseibacillus rhamnosus HA-114 | “Our aim was to determine if Lacticaseibacillus rhamnosus HA-114 supplementation accentuated beneficial impact of weight loss on metabolic and cognitive health.” PMID 35714163 ↗ Jun 2022 |